Literature DB >> 25392109

Omega-3 fatty acids: a novel resort against gastrointestinal injury.

G Ianiro1, F Franceschi, S Bibbò, A Gasbarrini.   

Abstract

The integrity of gastric barrier derives from the balance between defending and damaging factors. In particular, prostaglandins play a relevant role in the maintenance of gastric homeostasis and prevention of peptic disease, at different levels. Omega-3 fatty acids, particularly eicosapentanoic acid, are the precursors of the third series of prostaglandins (with anti-inflammatory properties), also reducing the formation of the second series of prostaglandins (pro-inflammatory ones). Such a pathophysiological rationale brought to the experimental application, both in animal models and, more recently, in humans, of omega-3 fatty acids against gastrointestinal damage. Omega-3 fatty acids have shown interesting results in preventing different types of gastric damage in mouse models. A large retrospective case-control study on patients taking both anti-thrombotic therapy and eicosapentanoic acid showed (although only at unadjusted analysis) an inverse correlation between consumption of eicosapentanoic acid and gastrointestinal injury. Prospective, well-designed, comparative studies are warranted to clarify if omega-3 fatty acids may represent, or not, a novel resort against gastrointestinal injury.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25392109

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

Review 1.  Targeting inflammation in metabolic syndrome.

Authors:  Francine K Welty; Abdulhamied Alfaddagh; Tarec K Elajami
Journal:  Transl Res       Date:  2015-07-03       Impact factor: 7.012

2.  Effects of Concurrent Omega-3 and Cranberry Juice Consumption Along with Standard Antibiotic Therapy on the Eradication of Helicobacter pylori, Gastrointestinal Symptoms, Some Serum Inflammatory and Oxidative Stress Markers in Adults with Helicobacter pylori Infection: A Study Protocol for a Randomized Controlled Trial.

Authors:  Ahmad Zare Javid; Leila Maghsoumi-Norouzabad; Hadi Bazyar; Vahideh Aghamohammadi; Pejman Alavinejad
Journal:  Infect Drug Resist       Date:  2020-09-15       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.